Evolución de 37 pacientes con compromiso renal

Actualización en Granulomatosis de Wegener

La afectación renal al hacerse el diagnóstico de GW es un predictor de mal pronóstico y poca supervivencia.

Autor/a: Dres. Jacques-E. Gottenberg, Alfred Mahr, Christian Pagnoux, Pascal Cohen, L Mouthon, Loïc Guillevin

Fuente: Presse Med. 2007; 36: 771–8

Indice
1. Referencias
2. Desarrollo

1. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992; 116:488-98.
2. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983; 98: 76-85.
3. Reinhold-Keller E, Beuge N, Latza U, de Groot K, Rudert H, Nolle B et al. An Interdisciplinary approach to the care of patients with Wegener’s granulomatosis: long-term outcome in 155 patients. Arthritis Rheum. 2000; 43:1021-32.
4. Lê Thi Huong D, Wechsler B, de Gennes C, Raguin G, Piette JC, Blétry O et al. Evolutive and prognostic aspects of Wegener’s granulomatosis. Rev Rhum Mal Osteoartic. 1989;56:583-8.
5. Briedigkeit L, Kettritz R, Gobel U, Natusch R. Prognostic factors in Wegener’s granulomatosis. Postgrad Med J. 1993; 69: 856-61.
6. Koldingsnes W, Nossent H. Predictors of survival and organ damage in Wegener’s granulomatosis. Rheumatol. 2002; 41: 572-81.
7. Weidner S, Geuss S, Hafezi-Rachti S, Wonka A, Rupprecht HD. ANCA-associated vasculitis with renal involvement: an outcome analysis. Nephrol Dial Transplant. 2004; 19:1403-11.
8. Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum. 1997; 40: 2187-98.
9. Kaplan E, Meier P. Non parametric estimation for incomplete information. J Ann Stat Assoc. 1958; 53: 457-81.
10. Cox D. Regression models and life tables. J R Stat Soc [Ser A]. 1972; 34:187-219.
11. Anderson G, Coles ET, Douglas AC, Crane M, Gibbs AR, Geddes DM et al. Wegener’s  granuloma. A series of 265 British cases seen between 1975 and 1985. A report by a subcommittee of the British Thoracic Society Research Committee. Q J Med. 1992; 83:427-38.
12. Aasarod K, Iversen BM, Hammerstrom J, Bostad L, Vatten L, Jorstad S. Wegener’s granulomatosis: clinical course in 108 patients with renal involvement. Nephrol Dial Transplant. 2000; 15: 611-8.
13. Slot MC, Tervaert JWC, Franssen CFM, Stegeman CA. Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. Kidney Int. 2003; 63: 670-7.
14. Luqmani RA, Bacon PA, Beaman M et al. Classical versus non-renal Wegener’s granulomatosis. Q J Med. 1994; 87:161-7.
15. Matteson EL, Gold KN, Bloch DA, Hunder GG. Long-term survival of patients with Wegener’s granulmatosis from the American College of Rheumatology. Wegener’s Classification Criteria Cohort. Am J Med. 1996; 101:129-34.
16. Koldingsnes W, Nossent JC. Baseline features and initial treatment as predictors of remission and relapse in Wegener’s granulomatosis. J Rheumatol. 2003; 30: 80-8.
17. Stegeman CA, Tervaert JWC, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CGM. Association of chronic nasal carriage of Staphylococcus Aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med. 1994; 120:12-7.
18. Bligny D, Mahr A, Le Toumelin T, Mouthon L, Guillevin L. Predicting mortality in systemic Wegener’s granulomatosis: a survival analysis based on 93 patients. Arthritis Rheum. 2004; 51:83-91.
19. Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis. 2003; 41:776-4.
20. Hauer HA, Bajema IM, van Houwelingen HC, Ferrario F, Noel LH, Waldherr R et al. Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinicohistopathological analysis of 96 patients. Kidney Int. 2002; 62: 1732-42.
21. Vergunst CE, van Gurp E, Hagen EC, van Houwelingen HC, Hauer HA, Noel LH et al. An index for renal outcome in ANCAassociated glomerulonephritis. Am J Kidney Dis. 2003; 41:532-8.
22. Neumann I, Regele H, Kain R, Birck R, Meisl FT. Glomerular immune deposits are associated with increased proteinuria in patients with ANCA-associated crescentic nephritis. Nephrol Dial Transplat. 2003; 18: 524-31.
23. Kaplan-Pavlovcic S, Cerk K, Kveder R, Lindic J, Vizjak A. Clinical prognostic factors of renal outcome in anti-neutrophil cytoplasmic autoantibody (ANCA)-associated glomerulonephritis in elderly patients. Nephrol Dial Transplant. 2003;18:v5-v7.
24. Westman KW, Bygren PG, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener’s granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol. 1998; 9: 842-52.
25. Spriewald BM, Witzke O, Wassmuth R, Wenzel RR, Arnold ML, Philipp T et al. Distinct tumour necrosis factor a, interferon g, interleukin 10, and cytotoxic T cell antigen 4 gene polymorphisms in disease occurrence and end stage renal disease in Wegener’s  granulomatosis. Ann Rheum Dis. 2005; 64: 457-61.
26. Vassallo M, Shepherd RJ, Iqbal P, Feehally I. Age-related variations in presentation and outcome in Wegener’s graulomatosis. J R Coll Physicians Lond. 1997; 31: 396-400.
27. Krafcik SS, Covin RB, Lynch 3rd JP, Sitrin RG. Wegener’s granulomatosis in the elderly. Chest. 1996; 109: 430-7.
28. Lê Thi Huong D, Wechsler B, Piette JC, de Gennes C, Cabane J, Bletry O et al. Granulomatose de Wegener du sujet âgé : 37 cas. Presse Med. 1988; 17:2379-82.
29. Haubitz M, Schellong S, Gobel U, Schurek HJ, Schaumann D, Koch KM et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum. 1998; 41:1835-44.
30. Gaskin G, Jayne DR, European Vasculitis Study Group. Adjunctive plasma exchange is superior to methylprednisolone in acute renal failure due to ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2002; 13: 2A.